Posts tagged data
BioLight posts positive latanoprost insert data

BioLight Life Sciences (TASE:BOLT) announced successful results from its glaucoma insert, VS101, (Eye-D latanoprost) in a Phase 1/2a clinical trial, which demonstrated its ability to lower intraocular pressure (IOP) for a 12-week period, with a favorable safety profile.

Read More
Theratechnologies presents new HIV findings

Theratechnologies’ (TSX:TH) presented results on HIV susceptibility to ibalizumab from a Phase 2b trial, along with new findings for EGRIFTA (tesamorelin for injection), at the 9th IAS Conference on HIV Science in Paris.

Read More
Leerink ups Immunogen to OP from MP

Leerink upgraded Immunogen (NASDAQ:IMGN) to “outperform” from “market perform” and raised its price target to $8 from $2 based on a “higher level of conviction” on lead asset, mirvetuximab soravtansine, providing an attractive risk/reward in context of the stock's current valuation. The stock closed at $3.24 on April 18.

Read More
Stifel downgrades Nivalis to hold

Stifel downgraded Nivalis Therapeutics (NASDAQ:NVLS) to “ hold” from “buy” and slashed its price target to $3.25 from $16 after the company released Phase 2 data for cavosonstat in the treatment of patients with homozygous F508del CF that were stably on Orkambi. The stock closed at $6.25 on Monday.

Read More
Canaccord and BTIG start iRhythm at buy

BTIG initiated coverage of iRhythm Technologies (NASDAQ:IRTC) with a “buy” rating and a $28 price target. The stock closed at $24.23 on Friday.

iRhythm is a digital health care company redefining the way cardiac arrhythmias are clinically diagnosed. The company combines wearable biosensor devices worn for up to 14 days and cloud-based data analytics with powerful proprietary algorithms that distil data from millions of heartbeats into clinically actionable information.

Read More
Echelon ups RepliCel price target to $2.15

Echelon Wealth Partners raised its price target for RepliCel Life Sciences (TSX-V:RP) to $2.15 from $1.50 after the company closed a unit offering that will add about $4.1-million in net cash to its balance sheet. The stock closed at $1.03 on Monday.

“The recapitalization provides funds to drive [RepliCel’s hair follicle-derived] non-bulbar dermal sheath cell platform forward with renewed vigor,” writes analyst Doug Loe, noting that he expects interim six-month data from a Phase 1/2 Achilles tendinosis/RCT-01 study by yearend.

Read More
Titan’s Probuphine featured at ISAM meeting

Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine implant and marketing partner, closely-held Braeburn Pharmaceuticals, were featured in three presentations at the International Society of Addiction Medicine (ISAM) annual meeting in Montreal last week.

Probuphine, a subdermal implant of buprenorphine, is the first commercially available six-month maintenance treatment for opioid dependence. The FDA approved Probuphine in May.

Read More
Dipexium updates availability of Phase 3 data

Dipexium Pharmaceuticals (NASDAQ:DPRX) updated the status of results from two pivotal Phase 3 clinical trials - OneStep-1 and OneStep-2- of its topical antimicrobial peptide, Locilex, for the treatment of diabetic foot ulcers.

Data tables and listings from both of these trials are currently being produced and evaluated by the company's scientific advisors according to a pre-specified data review procedure. 

Read More
Anavex reports Phase 2a efficacy data in AD

Anavex Life Sciences (NASDAQ:AVXL) announced efficacy data through 31 weeks from the ongoing ANAVEX 2-73 Phase 2a study in mild-to-moderate Alzheimer’s patients at the Alzheimer’s Association International Conference in Toronto.

Read More
Anavex presents safety data in AD

Anavex Life Sciences (NASDAQ:AVXL) presented safety data for its ANAVEX 2-73 drug candidate at the Alzheimer’s Association International Conference 2016 in Toronto.

Data presented in a poster highlights the evaluation of a maximum tolerated dose of ANAVEX 2-73 as primary endpoint of the Phase 2a study in mild-to-moderate Alzheimer’s patients, as well as additional clinical safety data and positive unexpected therapeutic response events, such as improved mood, improved social engagement and increased independent activities through 31 weeks.

Read More
Maxim cuts Celsion price target to $4

Maxim Group cut its price target for “buy-rated” Celsion (NYSE:CLSN) to $4 from $9. The stock was quoted at $1.22 Friday afternoon.

“While we are believers in Celsion’s ThermoDox product and platform, we recognize that pivotal Phase 3 data [from the OPTIMA study] will not arrive until late 2018,” writes analyst Jason McCarthy.

Read More
HCW assumes coverage of Vical at buy

H.C. Wainwright analyst Shaunak Deepak assumed coverage of Vical (NASDAQ:VICL) with a “buy” rating and $12 price target. The stock was quoted at $4.39, up 3 cents, Tuesday afternoon.

“With a co-marketable asset in Phase 3 development that is fully funded by partner, Astellas, and a diversified clinical pipeline, we believe Vical should be trading above cash,” Mr. Deepak writes.

Read More
Stifel starts Selecta Biosciences at buy

Stifel launched coverage of Selecta Biosciences (NASDAQ:SELB) with a “buy” rating and $23 price target. The stock closed at $14 on Friday.

“Selecta’s SVP-Rapamycin technology has the potential to open the doors of immunological tolerance and allow patients to be treated with recombinant protein ‘creations’ designed to combat disease,” writes analyst Thomas Shrader.

Read More
BTIG starts Insulet, Intersect at neutral

BTIG Research initiated research of Insulet (NASDAQ:PODD) and Intersect ENT (NASDAQ:XENT) with “neutral” ratings. Shares of Insulet closed at $32.21 and shares of Intersect at $13.51 on Tuesday.

Analyst Sean Lavin writes that he sees Insulet’s core business as fairly valued at five times next 12 months revenue as both the major upside events and key risks are hard to forecast in terms of timing. 

Read More
HCW analyst assumes coverage of Celsion

H.C. Wainwright analyst Swayampakula Ramakanth has assumed coverage of Celsion (NASDAQ:CLSN) with a “buy” rating and $3 price target. The stock closed at $1.30 on Monday.

Celsion has developed two cancer therapeutic platforms: LTSL for the delivery of chemotherapies and TheraPlas for the delivery of therapeutic DNA, RNA or proteins, both of which allow drugs to be delivered locally at high concentrations for greater therapeutic benefit and lower toxicity.

Read More
HCW starts Anthera Pharma at buy

H.C. Wainwright initiated coverage of Anthera Pharmaceuticals (NASDAQ:ANTH) with a “buy” rating and $10 price target. The stock closed at $3.38 on Thursday.

“We believe that at this time Anthera’s pipeline and value proposition has bifurcated into two components of very different risk/reward,” writes analyst Andrew Fein.

Read More
Roth resumes coverage of CymaBay

Roth Capital Partners has resumed coverage of CymaBay Therapeutics (NASDAQ:CBAY) with a “buy” rating and $4 price target. The stock closed at $1.57 on Friday.

“In our opinion, while catalysts for the next 12-to-18 months are limited, the potential partnering of arhalofenate could be a significant driver for the shares, enhancing CymaBay’s coffers, validating the company’s approach, bridging the catalyst gap until additional data can be gleaned from MBX-8025’s HoFH and PBC programs, and increasing confidence in management’s execution,” writes analyst Sa’ar Yaniv.

Read More
Roth resumes coverage of Galectin Therapeutics

Roth Capital Partners resumed coverage of Galectin Therapeutics (NASDAQ:GALT) with a “buy” rating and $3 price target. The stock closed at $1.52 on Friday.

“In our opinion, Phase 1 data demonstrated Galectin’s GR-MD-02’s positive effect on NASH fibrosis biomarkers,” writes analyst Sa’ar Yaniv.

Read More
Fibrocell Phase 2 vocal scaring trial fails

A Phase 2 clinical trial of Fibrocell Science’s (NASDAQ:FCSC) azficel-T for the treatment of vocal cord scarring resulting in chronic or severe dysphonia failed to meet its primary endpoints.

Fibrocell intends to focus its efforts on the development of FCX-007 for the treatment of recessive dystrophic epidermolysis bullosa and its earlier-stage programs.

Read More
Dipexium completes enrollment in second Phase 3 trial

Dipexium Pharmaceuticals (NASDAQ:DPRX) has completed patient enrollmentin the OneStep-1 pivotal Phase 3 clinical trial of its Locilex broad-spectrum, topical antibiotic peptide.

Last week, the company reached the enrollment objective in the OneStep-2 pivotal trial.

Read More